Drug Trial Radar · NCT00911326
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
Last checked: Nov 20, 2026Latest source record: Aug 8, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
101
Actual
Start
May 2009
Primary completion
Aug 2013
Study completion Aug 2013
Sponsor
- Lead sponsor
- Navidea BiopharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jun 1, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the false negative rate (FNR) associated with Lymphoseek-identified sentinel lymph nodes (SLNs) relative to the pathological status of non-sentinel lymph nodes in elective neck dissection (END) in head \& neck squamous cell carcinoma (HNSCC). NEO3-06 (this study) is a Phase 3 clinical trial designed to supplement NEO3-05, a completed Phase 3 clinical trial conducted in patients with breast cancer or melanoma. NEO3-05 was designed to establish Lymphoseek as an effective radio-diagnostic agent to be used in the intraoperative localization of lymph tissue (nodes) in the lymphatic pathway draining the primary site of a tumor.
Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
LymphoseekDrug
Single injection of 50 micrograms Lymphoseek radiolabeled with either 0.5 mCi (for same day surgery) or 2.0 mCi (for next day surgery) of Tc 99m
Primary outcomes
What the sponsor says the trial is designed to measure.
- False Negative Rate (FNR)Time frame: Surgery after injection of Lymphoseek
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama, Birmingham
Birminham, Alabama
Moores UCSD Cancer Center
La Jolla, California
San Diego VA Hospital
San Diego, California
University of Miami, Sylvester Comprehensive Cancer Center
Miami, Florida
University of Kansas Medical Center
Kansas City, Kansas
University of Michigan Medical Center
Ann Arbor, Michigan
University of Mississippi
Jackson, Mississippi
University of Missouri-Ellis Fischel Cancer Center
Columbia, Missouri
University of Nebraska
Omaha, Nebraska
Duke University Medical Center
Durham, North Carolina
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Thomas Jefferson University
Philadelphia, Pennsylvania
MD Anderson
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.